180 related articles for article (PubMed ID: 23981264)
1. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
2. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
[TBL] [Abstract][Full Text] [Related]
3. What is the budget impact of a new treatment or new health technology arriving on the market?
Dervaux B; Le Fur C; Dubois S; Josseran A;
Therapie; 2017 Feb; 72(1):93-103. PubMed ID: 28159198
[TBL] [Abstract][Full Text] [Related]
4. Telemedicine: what framework, what levels of proof, implementation rules.
Zannad F; Maugendre P; Audry A; ; Avril C; Blaise L; Blin O; Burnel P; Falise-Mirat B; Girault D; Giri I; Goehrs JM; Lassale C; Le Meur R; Leurent P; Ratignier-Carbonneil C; Rossignol P; Satonnet E; Simon P; Treluyer L
Therapie; 2014; 69(4):339-54. PubMed ID: 25230356
[TBL] [Abstract][Full Text] [Related]
5. The European "clinical trial" regulation; relationship with the Jardé Act: a Giens workshop.
Lemaire F; Marchenay B; Chassany O; ; Barthélémy P; Bouzzagou M; Comet D; Delval C; Dubray C; Fouret C; Frija-Orvoen E; Gambotti L; Lamarque V; d'Orsay G; Plattner V; Sibenaler C; Roux J; Thoby F
Therapie; 2015; 70(1):21-36. PubMed ID: 25679191
[TBL] [Abstract][Full Text] [Related]
6. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
[TBL] [Abstract][Full Text] [Related]
7. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
8. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
9. [Generic drugs in the medical-economic context of drug prescriptions].
Bouvenot G; Villani P; Bouvenot J
Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
[TBL] [Abstract][Full Text] [Related]
10. [The benefit provided by new medicinal products in 2005-2006--the viewpoint of the French National Authority for Health].
Bouvenot G
Therapie; 2007; 62(5):387-91. PubMed ID: 18206101
[TBL] [Abstract][Full Text] [Related]
11. Social Security cost-of-living adjustments and the Consumer Price Index.
Burdick C; Fisher L
Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
[TBL] [Abstract][Full Text] [Related]
12. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
13. [The French medecine pricing committee].
Giorgi D
Ann Pharm Fr; 2017 Sep; 75(5):373-384. PubMed ID: 28583317
[TBL] [Abstract][Full Text] [Related]
14. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
[TBL] [Abstract][Full Text] [Related]
15. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
16. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
Berdaï D; Hotton JM; Lechat P;
Therapie; 2010; 65(4):329-34. PubMed ID: 20854755
[TBL] [Abstract][Full Text] [Related]
17. Lifetime earnings patterns, the distribution of future Social Security benefits, and the impact of pension reform.
Bosworth B; Burtless G; Steuerle E
Soc Secur Bull; 2000; 63(4):74-98. PubMed ID: 11641991
[TBL] [Abstract][Full Text] [Related]
18. Current process and future path for health economic assessment of pharmaceuticals in France.
Toumi M; Rémuzat C; El Hammi E; Millier A; Aballéa S; Chouaid C; Falissard B
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123173
[TBL] [Abstract][Full Text] [Related]
19. Six Sigma: not for the faint of heart.
Benedetto AR
Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
[TBL] [Abstract][Full Text] [Related]
20. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
